Wells Fargo’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-7,784
| Closed | -$14.4K | – | 7784 |
|
|
2023
Q1 | $14.4K | Buy |
7,784
+7,466
| +2,348% | +$9.25K | ﹤0.01% | 5741 |
|
|
2022
Q4 | $353 | Sell |
318
-84
| -21% | -$120 | ﹤0.01% | 6480 |
|
|
2022
Q3 | $1K | Sell |
402
-392
| -49% | -$1.39K | ﹤0.01% | 6549 |
|
|
2022
Q2 | $2K | Sell |
794
-57,702
| -99% | -$281K | ﹤0.01% | 6428 |
|
|
2022
Q1 | $397K | Sell |
58,496
-8,999
| -13% | -$64.1K | ﹤0.01% | 4573 |
|
|
2021
Q4 | $564K | Sell |
67,495
-124,231
| -65% | -$1.02M | ﹤0.01% | 4570 |
|
|
2021
Q3 | $1.42M | Buy |
191,726
+46,815
| +32% | +$290K | ﹤0.01% | 3941 |
|
|
2021
Q2 | $985K | Sell |
144,911
-98,043
| -40% | -$814K | ﹤0.01% | 4216 |
|
|
2021
Q1 | $2.5M | Buy |
242,954
+130,366
| +116% | +$1.43M | ﹤0.01% | 3499 |
|
|
2020
Q4 | $788K | Buy |
112,588
+20,238
| +22% | +$158K | ﹤0.01% | 4199 |
|
|
2020
Q3 | $753K | Buy |
92,350
+8,910
| +11% | +$55.2K | ﹤0.01% | 4069 |
|
|
2020
Q2 | $576K | Buy |
83,440
+9,409
| +13% | +$50.8K | ﹤0.01% | 4225 |
|
|
2020
Q1 | $351K | Buy |
74,031
+17,911
| +32% | +$103K | ﹤0.01% | 4301 |
|
|
2019
Q4 | $490K | Buy |
56,120
+11,101
| +25% | +$60K | ﹤0.01% | 4389 |
|
|
2019
Q3 | $150K | Buy |
45,019
+6,163
| +16% | +$24.7K | ﹤0.01% | 5131 |
|
|
2019
Q2 | $191K | Sell |
38,856
-567
| -1% | -$3.01K | ﹤0.01% | 5005 |
|
|
2019
Q1 | $244K | Sell |
39,423
-7,759
| -16% | -$37.5K | ﹤0.01% | 4723 |
|
|
2018
Q4 | $158K | Buy |
47,182
+8,568
| +22% | +$40K | ﹤0.01% | 5071 |
|
|
2018
Q3 | $251K | Sell |
38,614
-110
| -0.3% | -$818 | ﹤0.01% | 4877 |
|
|
2018
Q2 | $297K | Buy |
38,724
+1,128
| +3% | +$16.3K | ﹤0.01% | 4810 |
|
|
2018
Q1 | $840K | Sell |
37,596
-4,312
| -10% | -$95.7K | ﹤0.01% | 4040 |
|
|
2017
Q4 | $534K | Buy |
41,908
+21,127
| +102% | +$311K | ﹤0.01% | 4348 |
|
|
2017
Q3 | $324K | Sell |
20,781
-189
| -0.9% | -$2.67K | ﹤0.01% | 4625 |
|
|
2017
Q2 | $294K | Buy |
20,970
+17,330
| +476% | +$371K | ﹤0.01% | 4546 |
|
|
2017
Q1 | $80K | Buy |
+3,640
| New | +$77.1K | ﹤0.01% | 5284 |
|
Other funds holding JNCE
Wells Fargo's JNCE Position: Q2 2023 in Review
Wells Fargo sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 7,784 shares — an estimated $14.4K sold.
Wells Fargo first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $2.5M in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Wells Fargo reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Wells Fargo sold 7,784 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $14.4K.
- Wells Fargo first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Wells Fargo's Jounce Therapeutics, Inc. Common Stock position peaked at $2.5M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Wells Fargo's 13F filing for Q2 2023, filed 15 Aug 2023.